Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
British Journal of Haematology|December 12, 2001
Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplantR Pawson, M N Potter, P Theocharous, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|May 5, 2020
Noninvasive prenatal diagnosis for pregnancies at risk for β-thalassaemia: a retrospective studyW Lv, S Linpeng, Z Li, et al.
Leukemia|November 8, 2014
A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemiaN H Russell, L Kjeldsen, C Craddock, et al.
Clinical Radiology|March 1, 1986
Non-Hodgkin's lymphoma: a survey from a district general hospitalA B Mehta, J P Evans, T O Kumaran, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]|July 12, 2018
[Analysis on maternal anemia rate and related factors in Taicang of Jiangsu Province in 2014-2016]F Li, C Zhang, Y G Chen, et al.
Optics Express|June 3, 2009
Optical properties of waveguides written by a 26 MHz stretched cavity Ti:sapphire femtosecond oscillatorRoberto Osellame, N Chiodo, V Maselli, et al.
The Tohoku Journal of Experimental Medicine|May 1, 1997
Nutritional evaluation of women in urban areas in continental ChinaZ W Zhang, J B Qu, C S Moon, et al.
British Journal of Haematology|June 1, 1996
Evaluation of cytogenetic conversion to Ph- haemopoiesis in long-term bone marrow culture for patients with chronic myeloid leukaemia on conventional hydroxyurea therapy, on pulse high-dose hydroxyurea and on interferon-alphaL H Coutinho, M L Brereton, A M Santos, et al.
British Journal of Haematology|October 3, 2002
Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimensJane E Parker, Tariq Shafi, Antonio Pagliuca, et al.
Blood|November 26, 1999
A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemiaE Archimbaud, O G Ottmann, J A Yin, et al.
Pageof 12